Publication in application of Article 15 of the Law of 2 May 2007 
                      (the Transparency Law) 

Acacia Pharma Group plc

As previously announced(1) , Acacia Pharma Group plc issued ordinary shares to its Employee Benefit Trust within the authorised capital. The gross amount of this capital increase amounted to GBP 22,909.44 via an issue of 1,145,472 new shares at an issue price of GBP 0.02 per share. The shares were issued to satisfy the vesting of share awards granted under the Company's Performance Share Plan.

Total amount of share capital on 21 
 December 2021                          GBP 2,017,188.46 
-------------------------------------  ------------------ 
Total amount of share premium on 21 
 December 2021                         GBP 142,087,474.57 
-------------------------------------  ------------------ 
Total number of shares with voting 
 rights on 21 December 2021                   100,859,423 
-------------------------------------  ------------------ 
Total number of voting rights on 21 
 December 2021 (denominator)                  100,859,423 
-------------------------------------  ------------------ 
Total number of outstanding warrants              201,330 
-------------------------------------  ------------------ 
Total number of outstanding employee 
 share options and RSUs(2)                      6,208,505 
-------------------------------------  ------------------ 
   1. Press release of 16 December 2021 -- Issue of Shares to Employee Benefit 
   2. Of the 6,208,505 options and RSUs currently outstanding, 1,015,583 will 
      be satisfied through the transfer of shares already issued and admitted 
      to trading and held within the Acacia Pharma Group plc Employee Benefit 


Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Frazer Hall, Mark Swallow, David 
 Gary Gemignani, CFO                              Dible 
 +44 1223 919760 / +1 317 505 1280                MEDiSTRAVA Consulting 
 mailto:IR@acaciapharma.com IR@acaciapharma.com   +44 20 7638 9571 
-----------------------------------------------  ------------------------------------ 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    +32 499 58 55 31 
 +1 917-734-7387                                  mailto:chrisvanraemdonck@telenet.be 
 mailto:ikoffler@lifesciadvisors.com              chrisvanraemdonck@telenet.be 
-----------------------------------------------  ------------------------------------ 

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Barhemsys(R) (amisulpride) injection is a selective dopamine (D2 and D3) receptor antagonist approved and available in the US for the treatment and prevention of postoperative nausea & vomiting (PONV) in adult patients.

Please see full prescribing information, including Important Safety Information, at https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVO93Qv7wPBwdQJkVEtHY9WQ_OzhUXfUGgMwsF9C-9W6WO8ISpRzCjsdecLPlmE24Sf-57ygnB5nwRLSnIzdK5rciSOfhYLSMMMrc3qWD9WpRxr0iPjhHGG-8JyJBktvPN0V3r62ekFYx4qZz-c_4ksTZYDLfj5RskzNJ7RSZUJNjRWXEDP6giUYhHse4-YhXHxUjmDlc1--9jgKiD2n_vnPs= www.BARHEMSYS.com.

Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine sedative approved and available in the US for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Byfavo is in-licensed from Paion UK Limited for the US market.

Please see full prescribing information, including Important Safety Information and Boxed Warning, at https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVOzsiWH4oPakS6-ZuJoJBMiFvLR-CpxNuXh15zXdAX4-SPCZaFw_NEl3iLtHI9z7YJjGjmuD4R1i47ZQ_CayPdNvFbrQ5RvvVN1n41eLU-6KxC2gowux9xJhNx5Ra83WGXb6bOQtN3PHXnvLkvRa5_EwTeTu3MO0C7MYSKiIrLhF9htDoCEAAN9WA75R_MGzdmoHyeFLhhHwZBi9hrSh2E9o= www.BYFAVO.com.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

This release is intended for investors and media only.

https://www.globenewswire.com/Tracker?data=68BDDhs2QH9xu9mDQHBVOzVN5m-MPs8LyrL-kTS6HWN8xLFSAuxyo1q0ZoeKNKrP6tdgknvsWlkwHu-cv7YDwG43Sd6jGlzXynBEWod_2Uk= www.acaciapharma.com


(END) Dow Jones Newswires

December 21, 2021 01:00 ET (06:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Acacia Pharma Charts.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Acacia Pharma Charts.